Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: Acta Biomater. 2018 Jun 22;76:29–38. doi: 10.1016/j.actbio.2018.06.027

Fig. 7. — Pretreatment by MATN3 maintains chondrogenesis and prevents hypertrophy and endochondral ossification in subcutaneous implants. The cell/scaffold constructs were cultured with growth medium or chondrogenic medium with or without MATN3 treatment for 3 weeks in vitro. The constructs were then subcutaneously implanted in athymic nude mice. Eight weeks post-surgery, the mice were euthanized and the implants were harvested for Safranin O, Von Kossa, and immunohistochemical staining to evaluate the maintenance of chondrogenesis and prevention of hypertrophy and endochondral ossification by MATN3 treatment in the 3D constructs in vivo, Scale bar=100 μm (A). Quantification of mineralization based on von Kossa staining (B).

Fig. 7. — Pretreatment by MATN3 maintains chondrogenesis and prevents hypertrophy and endochondral ossification in subcutaneous implants. The cell/scaffold constructs were cultured with growth medium or chondrogenic medium with or without MATN3 treatment for 3 weeks in vitro. The constructs were then subcutaneously implanted in athymic nude mice. Eight weeks post-surgery, the mice were euthanized and the implants were harvested for Safranin O, Von Kossa, and immunohistochemical staining to evaluate the maintenance of chondrogenesis and prevention of hypertrophy and endochondral ossification by MATN3 treatment in the 3D constructs in vivo, Scale bar=100 μm (A). Quantification of mineralization based on von Kossa staining (B).